Do Doctors Prescribe GLP-1? Biomarkers & Clinical Guidance

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, doctors prescribe GLP-1 agonists across primary care, endocrinology, and weight management settings. These medications are FDA-approved for type 2 diabetes management and chronic weight loss in adults with obesity or overweight status plus comorbidities. Recent data shows GLP-1 prescriptions increased 400% between 2020 and 2023, reflecting growing clinician confidence in this medication class.

Determining whether GLP-1 therapy is right for you requires more than simple eligibility criteria. Your provider considers metabolic biomarkers, glycemic control status, cardiovascular risk factors, and gastrointestinal tolerance. PlexusDx focuses on precision wellness by pairing evidence-based GLP-1 options with genetic insights into your peptide pathways, supporting a more informed provider conversation about personalized treatment.

Clinical Prescribing Criteria: When Doctors Recommend GLP-1 Therapy

Physicians prescribe GLP-1 agonists based on established clinical guidelines from the American Diabetes Association and American Society of Clinical Endocrinologists. For type 2 diabetes, GLP-1 is recommended when metformin alone is insufficient or when cardiovascular protection is a priority. For weight management, eligibility typically requires BMI ≥30 or BMI ≥27 with weight-related conditions like hypertension, dyslipidemia, or sleep apnea.

Prescribing decisions also factor in individual comorbidities and treatment history. Patients with established cardiovascular disease, heart failure, or chronic kidney disease often benefit from GLP-1's pleiotropic effects beyond glucose control. Your provider will review your current medication regimen, renal function, and personal or family history of medullary thyroid carcinoma before initiating therapy.

Biomarkers and Metabolic Context: Who Benefits Most from GLP-1

Beyond basic eligibility, several biomarkers inform GLP-1 prescribing intensity and choice of agent. HbA1c, fasting glucose, and postprandial glucose responses reveal glycemic control status. Lipid panels, inflammatory markers (hsCRP), and hepatic function assess cardiometabolic risk. GLP-1 agonists show differential efficacy depending on baseline metabolic phenotype, making individualized assessment essential.

Biomarker / Factor	Clinical Relevance to GLP-1 Therapy
HbA1c (glycemic control)	Baseline levels inform dose titration and efficacy expectations; <7% in many patients suggests adequate control.
Fasting insulin and HOMA-IR	High values indicate insulin resistance; GLP-1 may benefit through improved insulin sensitivity and beta-cell preservation.
GLP-1R and GIPR genetic variants	Predispositions in these peptide pathways may influence individual responsiveness; genetic test can provide contextual insights.
Lipid profile and hsCRP	Elevated triglycerides and inflammatory markers suggest cardiometabolic benefit from GLP-1 beyond weight loss alone.
eGFR and renal function	Normal renal function permits standard dosing; dose adjustments may apply with eGFR <15 mL/min/1.73m².

Medication Options and Provider Selection: Semaglutide vs. Tirzepatide

Doctors choose between GLP-1 monotherapy and dual GLP-1/GIP agonists based on patient response goals and tolerance. Semaglutide activates GLP-1 receptors, improving glycemic control and promoting modest weight loss. Tirzepatide, a GLP-1/GIP receptor agonist, provides greater weight loss and glycemic benefit in clinical trials, though both require careful dose escalation and gastrointestinal side effect monitoring.

Both agents are available as injectable formulations through licensed 503A compounding pharmacies, offering customized dosing regimens tailored to individual tolerance and response. Oral formulations exist in branded form, and compounded oral options provide alternative routes for patients with needle aversion. Your provider will discuss onset timing, injection frequency, and cost considerations when selecting the right option for your clinical context.

Safety Considerations and Provider Monitoring: Who Should and Should Not Use GLP-1

GLP-1 agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Caution is warranted in those with history of pancreatitis, proliferative retinopathy, severe gastrointestinal disease, or dehydration risk. Pregnancy is a contraindication; women of childbearing age require effective contraception during therapy and must discuss preconception planning with their provider.

Ongoing provider monitoring includes quarterly blood glucose checks, annual HbA1c and lipid panels, and annual kidney function assessment. Gastrointestinal side effects—nausea, vomiting, constipation—are common during dose escalation but often resolve with time or dose adjustment. Dehydration risk necessitates adequate fluid intake, especially during illness or hot weather. Regular follow-up ensures tolerability, efficacy, and early detection of any adverse signals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 receptor pathways (GLP1R rs6923761), GIP receptor pathways (GIPR rs1800437), and metabolic regulators (FTO rs9939609, MC4R rs17782313) that may help provide context for individual peptide pathway predispositions. While genetic variants do not predict exact medication response, they may illuminate foundational metabolic tendencies and receptor function relevant to your provider's treatment strategy. This genetic insight should be interpreted with a qualified healthcare provider as one part of a comprehensive clinical assessment.

The genetic test reveals predispositions in peptide genetic pathways—not pharmacogenomic or pharmacogenetic reactions to specific drugs. A patient with favorable GLP1R variants may have inherent advantages in GLP-1 signaling efficiency; those with certain FTO or MC4R predispositions might show different weight loss patterns or metabolic trajectories. These insights can support a more nuanced provider conversation about whether monotherapy, dual-compound therapy, or combination regimens align with your genetic and metabolic context.

Pairing genetic predisposition insights with clinical biomarkers and real-world tolerability data helps move beyond one-size-fits-all prescribing. When you share your genetic test results with your healthcare provider, you enable a more informed discussion about GLP-1 dosing strategy, compound selection, and monitoring intensity. This precision-wellness approach may help you and your provider align medication choice with your unique biology rather than standard population averages.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.